Compare WKHS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | LSTA |
|---|---|---|
| Founded | 2007 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 16.4M |
| IPO Year | N/A | N/A |
| Metric | WKHS | LSTA |
|---|---|---|
| Price | $4.74 | $4.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $21.00 | $15.00 |
| AVG Volume (30 Days) | 145.9K | ★ 363.6K |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,895,809.00 | $1,070,000.00 |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.74 | $1.81 |
| 52 Week High | $90.63 | $4.89 |
| Indicator | WKHS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 89.81 |
| Support Level | $4.77 | $2.05 |
| Resistance Level | $5.01 | $4.89 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | -0.15 | 0.25 |
| Stochastic Oscillator | 20.56 | 90.42 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.